Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Authors' Reply

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Assessment of Perfusion and Oxygenation of the Human Renal Cortex and Medulla by Quantitative MRI during Handgrip Exercise

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Genetic Landscape of Renal Complications in Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. SOS2 and ACP1 Loci Identified through Large-Scale Exome Chip Analysis Regulate Kidney Development and Function

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. SuPAR is associated with death and adverse cardiovascular outcomes in patients with suspected coronary artery disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Automatic oxygen titration with O2matic® to patients admitted with COVID-19 and hypoxemic respiratory failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  • International Study of Inflammation in COVID-19
View graph of relations

BACKGROUND: AKI commonly occurs in patients with coronavirus disease 2019 (COVID-19). Its pathogenesis is poorly understood. The urokinase receptor system is a key regulator of the intersection between inflammation, immunity, and coagulation, and soluble urokinase plasminogen activator receptor (suPAR) has been identified as an immunologic risk factor for AKI. Whether suPAR is associated with COVID-19-related AKI is unknown.

METHODS: In a multinational observational study of adult patients hospitalized for COVID-19, we measured suPAR levels in plasma samples from 352 adult patients that had been collected within 48 hours of admission. We examined the association between suPAR levels and incident in-hospital AKI.

RESULTS: Of the 352 patients (57.4% were male, 13.9% were black, and mean age was 61 years), 91 (25.9%) developed AKI during their hospitalization, of whom 25 (27.4%) required dialysis. The median suPAR level was 5.61 ng/ml. AKI incidence rose with increasing suPAR tertiles, from a 6.0% incidence in patients with suPAR <4.60 ng/ml (first tertile) to a 45.8% incidence of AKI in patients with suPAR levels >6.86 ng/ml (third tertile). None of the patients with suPAR <4.60 ng/ml required dialysis during their hospitalization. In multivariable analysis, the highest suPAR tertile was associated with a 9.15-fold increase in the odds of AKI (95% confidence interval [95% CI], 3.64 to 22.93) and a 22.86-fold increase in the odds of requiring dialysis (95% CI, 2.77 to 188.75). The association was independent of inflammatory markers and persisted across subgroups.

CONCLUSIONS: Admission suPAR levels in patients hospitalized for COVID-19 are predictive of in-hospital AKI and the need for dialysis. SuPAR may be a key component of the pathophysiology of AKI in COVID-19.

Original languageEnglish
JournalJournal of the American Society of Nephrology : JASN
Volume31
Issue number11
Pages (from-to)2725-2735
Number of pages11
ISSN1046-6673
DOIs
Publication statusPublished - Nov 2020

ID: 60897970